Methods for the treatment of depression and anxiety

Patent metadata

Field	Value
Publication number	US-9814755-B2
Application number	US-201514943936-A
Country	US
Kind code	B2
Filing date	Nov 17, 2015
Priority date	Jun 10, 2014
Publication date	Nov 14, 2017
Grant date	Nov 14, 2017

Abstract

Methods of treating a depressive disorder or an anxiety disorder in a subject in need of such treatment are described. A therapeutically effective amount of a composition comprising Ac-Nle 4 -c[Asp 5 -His 6 -(NMe)D-Nal(2′) 7 -Arg 8 -Trp 9 -(NMe)Lys 10 ]-NH 2 (PEPTIDE 9), in a pharmaceutically acceptable carrier is administered to the subject. PEPTIDE 9 is a selective MC5R antagonist, in which administration thereof to the subject can treat the depressive or generalized anxiety disorder with clinical improvement observed in a relatively short time.

First claim

What is claimed is:

1. A method of treating a depressive disorder or an anxiety disorder in a subject in need thereof, said method comprising administering to the subject a therapeutically effective amount of a composition comprising:
Ac-Nle 4 -c[Asp 5 -His 6 -(NMe)D-Nal(2′) 7 -Arg 8 -Trp 9 -(NMe)Lys 10 ]-NH 2 (PEPTIDE 9), in a pharmaceutically acceptable carrier.

2. The method of claim 1 , wherein the subject s a mammal.

3. The method of claim 1 , wherein the subject is a mammal, wherein the mammal is a human.

4. The method of claim 1 , wherein PEPTIDE 9 is an antagonist of melanocortin 5 receptor (MC5R).

5. The method of claim 1 , wherein PEPTIDE 9 is administered in a dosage of about 0.001 mg/kg to 100 mg/kg of body weight.

6. The method of claim 5 , wherein the composition is administered twice a day, daily, or every other day.

7. The method of claim 1 , wherein the composition is administered intranasally, intravenously, transdermally, or orally.

8. The method of claim 1 , wherein administration of the composition is combined with a non-pharmacological treatment for treating the depressive disorder or anxiety disorder in the subject.

9. The method of claim 8 , wherein the non-pharmacological treatment is psychotherapy, electroconvulsive therapy, transcranial magnetic stimulation, vagus nerve stimulation, acupuncture, hypnosis, meditation, an exercise regimen, or combinations thereof.

10. A method of treating a depressive disorder in a subject in need thereof, said method comprising administering to the subject a therapeutically effective amount of a composition comprising:
Ac-Nle 4 -c[Asp 5 -His 6 -(NMe)D-Nal(2′) 7 -Arg 8 -Trp 9 -(NMe)Lys 10 ]-NH 2 (PEPTIDE 9), in a pharmaceutically acceptable carrier.

11. The method of claim 10 , wherein the subject is a mammal.

12. The method of claim 10 , wherein the subject is a mammal, wherein the mammal is a human.

13. The method of claim 10 , wherein PEPTIDE 9 is an antagonist of melanocortin 5 receptor (MC5R).

14. The method of claim 10 , wherein PEPTIDE 9 is administered in a dosage of about 0.001 mg/kg to 100 mg/kg of body weight.

15. The method of claim 14 , wherein the composition is administered twice a day, daily, or every other day.

16. The method of claim 10 , wherein the composition is administered intranasally, intravenously, transdermally, or orally.

17. The method of claim 10 , wherein administration of the composition is combined with a non-pharmacological treatment for treating the depressive disorder or anxiety disorder in the subject.

18. The method of claim 17 , wherein the non-pharmacological treatment is psychotherapy, electroconvulsive therapy, transcranial magnetic stimulation, vagus nerve stimulation, acupuncture, hypnosis, meditation, an exercise regimen, or combinations thereof.

Assignees

• Univ Arizona

Inventors

• Hruby Victor J
• Cai Minying
• Kessler Horst

Classifications

• A61K38/177

  Receptors; Cell surface antigens; Cell surface determinants · CPC title

• A61K38/10

  Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)} · CPC title

• C07K14/685

  Alpha-melanotropin · CPC title

• A61K9/7084

  Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches · CPC title

• A61K9/0014

  Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00) · CPC title